Contact

Reaching a dermatology reference resource requires clear communication channels and accurate message content. This page outlines how inquiries are handled at National Dermatology Authority, what geographic scope the resource covers, and what information produces the most useful response. Understanding the structure of this contact process helps users frame medical, editorial, and regulatory questions appropriately.

Additional contact options

National Dermatology Authority is structured as an educational reference property, not a clinical practice. No appointment scheduling, prescription services, or patient record access is available through this platform. The distinction matters because the American Board of Dermatology (ABD) and the American Academy of Dermatology (AAD) separately maintain directories of licensed clinicians for those requiring direct clinical contact — the AAD's Find a Dermatologist tool allows filtering by specialty, location, and insurance acceptance.

For editorial inquiries — such as corrections to cited regulatory content, requests to clarify published information about skin conditions, or feedback on content drawn from sources like NIST SP 800-66 where health data security intersects with dermatological record-keeping — written correspondence through the site's contact form is the appropriate channel.

For questions referencing specific federal frameworks, including HIPAA Privacy Rule provisions at 45 CFR Part 164 or FDA regulatory guidance on prescription topical agents, identifying the specific rule or publication section in the message accelerates accurate editorial review.

How to reach this office

The primary contact method is the electronic form accessible from the site header and footer. Response windows vary by inquiry category:

1. Editorial corrections (factual errors, outdated regulatory citations, broken references to named agencies such as the FDA, CDC, or AAD): reviewed within 5 business days.
2. Content suggestions (proposed topic additions, gap identification in condition coverage): reviewed on a rolling basis, with priority given to conditions classified under ICD-10-CM Chapter 12 (Diseases of the Skin and Subcutaneous Tissue), the coding block covering L00–L99.
3. Accessibility or technical issues (page rendering, screen reader compatibility, WCAG 2.1 conformance concerns): flagged for technical review within 3 business days.
4. Research or academic inquiries (citation requests, methodology questions about source selection): handled editorially with no guaranteed response timeline.

No telephone line, live chat, or direct email address is publicly listed. This structure follows standard practice for reference-grade health information platforms operating under the FTC's guidelines on health information accuracy and the HHS Office for Civil Rights framework for consumer-facing health resources.

Service area covered

National Dermatology Authority covers dermatological topics within a United States national scope. Content is calibrated to U.S. regulatory frameworks, including:

• FDA drug approval pathways for topical and systemic dermatological agents
• Centers for Medicare and Medicaid Services (CMS) billing codes relevant to dermatological procedures, including CPT codes used for Mohs surgery, patch testing, and phototherapy
• State medical board licensing standards, which vary across all 50 states and the District of Columbia
• OSHA General Duty Clause standards as they apply to occupational skin conditions in industries with documented dermal exposure risk

Content is not calibrated to international regulatory frameworks such as the EMA (European Medicines Agency) or Health Canada, though named scientific literature from international sources (peer-reviewed journals indexed in PubMed) is cited where it establishes foundational clinical evidence applicable within the U.S. context.

Users located outside the United States may find the general educational content applicable, but regulatory and coverage information — including details covered on the dermatology insurance and coverage page — applies specifically to U.S. insurance markets and CMS structures.

What to include in your message

Message quality directly affects response accuracy. The following structured breakdown identifies what each inquiry type should contain:

For editorial corrections:
- The specific page URL or slug (e.g., /skin-cancer-types-and-warning-signs)
- The precise sentence or statistic in question
- The named public source that contradicts or updates the published content — acceptable sources include peer-reviewed publications, named federal agency documents (NIH, FDA, CDC, AAD guidelines), or official ICD/CPT coding updates from the AMA

For content suggestions:
- The condition, procedure, or regulatory topic not yet covered
- Whether the gap relates to a named classification system (ICD-10-CM, DSM-5, CPT, FDA drug schedule)
- Any named public source establishing clinical or regulatory relevance

For technical or accessibility issues:
- Browser name and version number
- Device type (desktop, mobile, tablet)
- The specific WCAG 2.1 success criterion affected, if known — the W3C publishes the full criterion list at w3.org/TR/WCAG21

Messages that omit a specific page reference, a named source, or a clear issue category take longer to route and may not receive a response if the subject cannot be identified from the content alone. No personally identifiable health information should be included in any message — this platform does not operate as a covered entity under HIPAA and is not equipped to handle or protect clinical patient data.

Privacy Policy

The law belongs to the people. Georgia v. Public.Resource.Org, 590 U.S. (2020)